Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in HypoparathyroidismJOURNAL OF BONE AND MINERAL RESEARCHIF5.92015-05-1924OAAI
A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of BoneJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMIF5.12014-11-0189OAAI
Optic Neuropathy in McCune-Albright Syndrome: Effects of Early Diagnosis and Treatment of Growth Hormone ExcessJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMIF5.12013-01-0151OA
Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structureJOURNAL OF BONE AND MINERAL RESEARCHIF5.92012-04-1073OAAI
Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal TumorsJOURNAL OF BONE AND MINERAL RESEARCHIF5.92010-12-0695OAAI
Cushing Syndrome in the McCune-Albright SyndromeJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMIF5.12010-04-0193OAAI
Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcomeJOURNAL OF BONE AND MINERAL RESEARCHIF5.92009-12-04134OAAI
Cinacalcet in the management of tumor-induced osteomalaciaJOURNAL OF BONE AND MINERAL RESEARCHIF5.92009-12-04107OAAI
An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of boneJOURNAL OF BONE AND MINERAL RESEARCHIF5.92009-12-04104OAAI
Fibroblast growth factor-23 is regulated by lα,25-dihydroxyvitamin DJOURNAL OF BONE AND MINERAL RESEARCHIF5.92009-12-0483OAAI
Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright SyndromeJOURNAL OF BONE AND MINERAL RESEARCHIF5.92009-12-02121OAAI
A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic featuresOSTEOPOROSIS INTERNATIONALIF5.42008-11-0443OA
Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesionsOSTEOPOROSIS INTERNATIONALIF5.42007-07-1186OAAI
Determination of the elimination half-life of fibroblast growth factor-23JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMIF5.12007-06-01131OAAI
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndromeJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMIF5.12006-08-0141OAAI
Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of boneBONEIF3.62005-09-0144PREAI